Saturday, July 11, 2026

Drug profile · INN

tapinarof

tapinarof (VTAMA) is a aryl hydrocarbon receptor agonist. Route of administration: topical. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — tapinarof
US status
approved
Class
Route
TOPICAL
Patents
0
Programs
1
Data quality
0.84

Quick answer

tapinarof (VTAMA) is a aryl hydrocarbon receptor agonist. Route of administration: topical. Current US regulatory status: approved.

Key facts

INN tapinarof
Brand VTAMA
Mechanism Aryl hydrocarbon receptor agonist
Target Aryl hydrocarbon receptor
Route TOPICAL
Formulation CREAM

Mechanism of action

Aryl hydrocarbon receptor agonist

Primary target: Aryl hydrocarbon receptor

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Tapinarof Cream 1% Phase 3 · Teva Pharma · Plaque Type Psorisis

Frequently asked questions

What is tapinarof?

tapinarof (VTAMA) is a aryl hydrocarbon receptor agonist. Route of administration: topical. Current US regulatory status: approved.

What is the brand name for tapinarof?

VTAMA is a marketed brand name for tapinarof. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tapinarof?

tapinarof has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.